Literature DB >> 18959827

Aliskiren combined with losartan: Thor's hammer or Sigurd's sword?

Thomas R Lux, Heinrich Taegtmeyer.   

Abstract

Entities:  

Year:  2008        PMID： 18959827     DOI： 10.1007/s11906-008-0081-3

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN： 1522-6417            Impact factor:   5.369


× No keyword cloud information.
  9 in total

1.  Increased adipose angiotensinogen gene expression in human obesity.

Authors:  V Van Harmelen; P Ariapart; J Hoffstedt; I Lundkvist; S Bringman; P Arner
Journal:  Obes Res       Date:  2000-07

2.  Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension.

Authors:  Nathaniel Berman; Thomas Hostetter
Journal:  Am J Kidney Dis       Date:  2008-02-11       Impact factor: 8.860

3.  ACE, angiotensinogen and obesity: a potential pathway leading to hypertension.

Authors:  R Cooper; N McFarlane-Anderson; F I Bennett; R Wilks; A Puras; D Tewksbury; R Ward; T Forrester
Journal:  J Hum Hypertens       Date:  1997-02       Impact factor: 3.012

4.  Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia)

Authors: 
Journal:  Lancet       Date:  1997-06-28       Impact factor: 79.321

5.  Proteinuria predicts end-stage renal failure in non-diabetic chronic nephropathies. The "Gruppo Italiano di Studi Epidemiologici in Nefrologia" (GISEN).

Authors:  P Ruggenenti; A Perna; L Mosconi; M Matalone; R Pisoni; F Gaspari; G Remuzzi
Journal:  Kidney Int Suppl       Date:  1997-12       Impact factor: 10.545

Review 6.  Physiology and pathophysiology of the adipose tissue renin-angiotensin system.

Authors:  S Engeli; R Negrel; A M Sharma
Journal:  Hypertension       Date:  2000-06       Impact factor: 10.190

7.  Central obesity and hypertension. Relationship between fasting serum insulin, plasma renin activity, and diastolic blood pressure in young obese subjects.

Authors:  G Licata; R Scaglione; A Ganguzza; S Corrao; M Donatelli; G Parrinello; M A Dichiara; G Merlino; M G Cecala
Journal:  Am J Hypertens       Date:  1994-04       Impact factor: 2.689

8.  Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives.

Authors:  M Azizi; G Chatellier; T T Guyene; D Murieta-Geoffroy; J Ménard
Journal:  Circulation       Date:  1995-08-15       Impact factor: 29.690

9.  Aliskiren combined with losartan in type 2 diabetes and nephropathy.

Authors:  Hans-Henrik Parving; Frederik Persson; Julia B Lewis; Edmund J Lewis; Norman K Hollenberg
Journal:  N Engl J Med       Date:  2008-06-05       Impact factor: 91.245
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.